NeuroPace (NPCE) Projected to Release Earnings on Tuesday

Key Points

• NeuroPace is expected to report Q3 2026 earnings after market close on Tuesday, November 3, with analysts forecasting a loss of $0.0862 per share and revenue of $27.13 million.
• In its previous quarter, the company reported a $0.18 per-share loss, beating estimates by $0.04, while revenue of $22.83 million exceeded expectations.
• Shares recently traded at $12.99, below their 50-day and 200-day moving averages. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $19.33.

NeuroPace (NASDAQ:NPCE - Get Free Report) is projected to issue its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect NeuroPace to post earnings of ($0.0862) per share and revenue of $27.13 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.04. NeuroPace had a negative net margin of 19.34% and a negative return on equity of 105.64%. The firm had revenue of $22.83 million for the quarter, compared to the consensus estimate of $22.61 million. On average, analysts expect NeuroPace to post ($0.67) EPS for the current fiscal year and ($0.21) EPS for the next fiscal year.

NeuroPace Trading Up 0.6%

NeuroPace stock opened at $12.99 on Tuesday. The company's fifty day simple moving average is $13.80 and its 200-day simple moving average is $15.06. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97. NeuroPace has a 12 month low of $9.22 and a 12 month high of $19.60. The stock has a market cap of $445.82 million, a P/E ratio of -22.79 and a beta of 1.86.

Analyst Ratings Changes

NPCE has been the topic of a number of recent research reports. Mizuho started coverage on NeuroPace in a research note on Thursday, July 23rd. They issued an "outperform" rating and a $22.00 target price on the stock. Guggenheim reissued a "neutral" rating on shares of NeuroPace in a research note on Wednesday, July 29th. KeyCorp initiated coverage on NeuroPace in a report on Thursday, September 17th. They issued an "overweight" rating and a $18.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of NeuroPace in a research report on Wednesday, July 29th. Finally, Raymond James Financial set a $21.00 target price on shares of NeuroPace in a research note on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, NeuroPace has a consensus rating of "Moderate Buy" and a consensus target price of $19.33.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company focused on developing and commercializing therapies for people with drug-resistant epilepsy. Its principal product is the RNS System, an implantable responsive neurostimulation device designed to detect abnormal electrical activity in the brain and deliver targeted stimulation intended to prevent or reduce seizures.

The RNS System includes an implanted neurostimulator, leads placed at or near seizure-onset areas, and a programming and data-management platform used by healthcare professionals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.